Insider · CIK 0001897621
Syed Ali-aamir Rizvi
Files at RCKT (ROCKET PHARMACEUTICALS, INC.), CRBU (Caribou Biosciences, Inc.), PSTX (Poseida Therapeutics, Inc.). First filing Jan 20, 2023, latest Jan 20, 2023.
In brief
Syed Ali-aamir Rizvi files SEC Form 4 as officer at CRBU (Caribou Biosciences, Inc.), and also at RCKT (ROCKET PHARMACEUTICALS, INC.), PSTX (Poseida Therapeutics, Inc.). Since Jan 20, 2023, Syed Ali-aamir Rizvi has reported 0 open-market buys worth $0 and 1 open-market sell worth $36k, the latest filed on Jan 20, 2023.
A track record needs three past buys with six months of prices behind them; Syed Ali-aamir Rizvi has 0, so none is measured yet.
The newest scored trade: sold $36k of CRBU on Jan 19, 2023, filed Jan 20, 2023, scored 21 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CRBU: Caribou Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | CRBUsell Caribou Biosciences, Inc. | $36k 5,627 shares | -9% | +23% from low-51% from high |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Common Stock | +61,963 | $0.00 | $0 | 407,874 | Feb 13, 2026 |
| Feb 11, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +93,037 | $0.00 | $0 | 93,037 | Feb 13, 2026 |
| Oct 6, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Common Stock | +283,018 | $0.00 | $0 | 283,018 | Oct 8, 2025 |
| Oct 6, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Common Stock | +62,893 | $0.00 | $0 | 345,911 | Oct 8, 2025 |
| Oct 6, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +383,854 | $0.00 | $0 | 383,854 | Oct 8, 2025 |
| Apr 1, 2024 | PSTX Poseida Therapeutics, Inc. | AGrant or award Common Stock | +185,000 | $0.00 | $0 | 185,000 | Apr 3, 2024 |
| Apr 1, 2024 | PSTX Poseida Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Apr 3, 2024 |
| Feb 21, 2023 | CRBU Caribou Biosciences, Inc. | AGrant or award Option to purchase Common Stockderivative | +131,000 | $0.00 | $0 | 131,000 | Feb 23, 2023 |
| Jan 19, 2023 | CRBU Caribou Biosciences, Inc. | SOpen-market sale Common Stock | -5,627 | $6.31 | $36k | 59,373 | Jan 20, 2023 |
Questions about Syed Ali-aamir Rizvi
Answered from the filings on this page, as of the latest one.
Is Syed Ali-aamir Rizvi buying or selling?
Not in the last 12 months. Syed Ali-aamir Rizvi's latest open-market trade on SEC Form 4 was sold $36k of CRBU on Jan 19, 2023.
How did Syed Ali-aamir Rizvi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Syed Ali-aamir Rizvi has 0.
Where does Syed Ali-aamir Rizvi file Form 4?
Syed Ali-aamir Rizvi has filed Form 4 at CRBU (Caribou Biosciences, Inc.) as Chief Medical Officer; RCKT (ROCKET PHARMACEUTICALS, INC.) as Chief Medical Officer; PSTX (Poseida Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.